Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

BACKGROUND Cancer stem cells are presumed to have virtually unlimited proliferative and self-renewal abilities and to be highly resistant to chemotherapy, a feature that is associated with overexpression of ATP-binding cassette transporters. We investigated whether prolonged continuous selection of cells for drug resistance enriches cultures for cancer stem-like cells. METHODS Cancer stem cells were defined as CD44+/CD24⁻ cells that could self-renew (ie, generate cells with the tumorigenic CD44+/CD24⁻ phenotype), differentiate, invade, and form tumors in vivo. We used doxorubicin-selected MCF-7/ADR cells, weakly tumorigenic parental MCF-7 cells, and MCF-7/MDR, an MCF-7 subline with forced expression of ABCB1 protein. Cells were examined for cell surface markers and side-population fractions by microarray and flow cytometry, with in vitro invasion assays, and for ability to form mammospheres. Xenograft tumors were generated in mice to examine tumorigenicity (n = 52). The mRNA expression of multidrug resistance genes was examined in putative cancer stem cells and pathway analysis of statistically significantly differentially expressed genes was performed. All statistical tests were two-sided. RESULTS Pathway analysis showed that MCF-7/ADR cells express mRNAs from ABCB1 and other genes also found in breast cancer stem cells (eg, CD44, TGFB1, and SNAI1). MCF-7/ADR cells were highly invasive, formed mammospheres, and were tumorigenic in mice. In contrast to parental MCF-7 cells, more than 30% of MCF-7/ADR cells had a CD44+/CD24⁻ phenotype, could self-renew, and differentiate (ie, produce CD44+/CD24⁻ and CD44+/CD24+ cells) and overexpressed various multidrug resistance-linked genes (including ABCB1, CCNE1, and MMP9). MCF-7/ADR cells were statistically significantly more invasive in Matrigel than parental MCF-7 cells (MCF-7 cells = 0.82 cell per field and MCF-7/ADR = 7.51 cells per field, difference = 6.69 cells per field, 95% confidence interval = 4.82 to 8.55 cells per field, P < .001). No enrichment in the CD44+/CD24⁻ or CD133+ population was detected in MCF-7/MDR. CONCLUSION The cell population with cancer stem cell characteristics increased after prolonged continuous selection for doxorubicin resistance.

[1]  J. P. Fonseca.  Drug Resistance and Cancer Stem Cells , 2012 .

[2]  M. Wicha,et al.  Single‐marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase , 2010, Head & neck.

[3]  Zuolin Wang,et al.  ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. , 2010, Biochemical and biophysical research communications.

[4]  Lin Zhang,et al.  Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers , 2010, PloS one.

[5]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[6]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[7]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[8]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[9]  E. Scott,et al.  Aldehyde dehydrogenase activity as a functional marker for lung cancer. , 2009, Chemico-biological interactions.

[10]  M. Dean.  ABC Transporters, Drug Resistance, and Cancer Stem Cells , 2009, Journal of Mammary Gland Biology and Neoplasia.

[11]  M. Wicha,et al.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion , 2008, Oncogene.

[12]  Anna E. Lokshin,et al.  Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.

[13]  M. Herlyn,et al.  Melanoma stem cells: the dark seed of melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Trumpp,et al.  Mechanisms of Disease: cancer stem cells—targeting the evil twin , 2008, Nature Clinical Practice Oncology.

[15]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[16]  C. D. Salcido,et al.  Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes , 2008, British Journal of Cancer.

[17]  Bin Zhang,et al.  Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. , 2008, Leukemia research.

[18]  Roy A Jensen,et al.  A human breast cell model of preinvasive to invasive transition. , 2008, Cancer research.

[19]  R. Clarke,et al.  Are stem-like cells responsible for resistance to therapy in breast cancer? , 2008, Breast disease.

[20]  D. Metzler,et al.  Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer , 2008, Journal of Cancer Research and Clinical Oncology.

[21]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[22]  C. D. Salcido,et al.  Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.

[23]  Archana Dhasarathy,et al.  The Transcription Factor Snail Mediates Epithelial to Mesenchymal Transitions by Repression of Estrogen Receptor - , 2007 .

[24]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[25]  A. Calcagno,et al.  ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. , 2007, Current drug delivery.

[26]  M. Wicha,et al.  Cancer stem cells: implications for cancer treatment and prevention. , 2007, Cancer journal.

[27]  S. Tucker,et al.  Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. , 2007, Cancer research.

[28]  S. Rutella,et al.  Expression of CD133-1 and CD133-2 in ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[29]  M. Waltham,et al.  Vimentin and Epithelial-Mesenchymal Transition in Human Breast Cancer – Observations in vitro and in vivo , 2007, Cells Tissues Organs.

[30]  Dana Ravid,et al.  A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. , 2007, Cancer letters.

[31]  Frank Pajonk,et al.  The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. , 2006, Journal of the National Cancer Institute.

[32]  T. Fojo,et al.  Characterization of Gene Rearrangements Leading to Activation of MDR-1*> , 2006, Journal of Biological Chemistry.

[33]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[34]  A. Calcagno,et al.  Plasma membrane calcium ATPase (PMCA4): A housekeeper for RT-PCR relative quantification of polytopic membrane proteins , 2006, BMC Molecular Biology.

[35]  B. Aggarwal,et al.  Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. , 2006, Cancer research.

[36]  E. D. de Vries,et al.  Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells. , 2006, Experimental hematology.

[37]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[38]  N. Kyprianou,et al.  Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? , 2005, Cancer research.

[39]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[40]  S. Hladky,et al.  Modulatory effects of plant phenols on human multidrug‐resistance proteins 1, 4 and 5 (ABCC1, 4 and 5) , 2005, The FEBS journal.

[41]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[42]  T. Lister,et al.  Characterization of Cells with a High Aldehyde Dehydrogenase Activity from Cord Blood and Acute Myeloid Leukemia Samples , 2005, Stem cells.

[43]  C. Richardson.  RAD51, genomic stability, and tumorigenesis. , 2005, Cancer letters.

[44]  O. Sieber,et al.  Genomic stability and tumorigenesis. , 2005, Seminars in cancer biology.

[45]  A. Howell,et al.  A putative human breast stem cell population is enriched for steroid receptor-positive cells. , 2005, Developmental biology.

[46]  D. Selwood,et al.  Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval , 2004, British Journal of Cancer.

[47]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[48]  V. Vasiliou,et al.  Role of Human Aldehyde Dehydrogenases in Endobiotic and Xenobiotic Metabolism , 2004, Drug metabolism reviews.

[49]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[50]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Klaus Pfizenmaier,et al.  Non-apoptotic Fas signaling. , 2003, Cytokine & growth factor reviews.

[52]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[53]  A. Multani,et al.  Multidrug-resistant MCF-7 cells: an identity crisis? , 2002, Journal of the National Cancer Institute.

[54]  A. Sahin,et al.  Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. , 2002, International journal of oncology.

[55]  Hoguen Kim,et al.  Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma , 2002, International journal of cancer.

[56]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[57]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[58]  P. Scheurich,et al.  The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. , 2001, Cellular signalling.

[59]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  S. Bates,et al.  Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. , 2000, Journal of the National Cancer Institute.

[61]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[62]  Melinda G. Hollingshead,et al.  Human Tumor Xenograft Models in NCI Drug Development , 1997 .

[63]  K. Mehta.  High levels of transglutaminase expression in doxorubicin‐resistant human breast carcinoma cells , 1994, International journal of cancer.

[64]  W. Birchmeier,et al.  Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. , 1994, Biochimica et biophysica acta.

[65]  M. Barrand,et al.  A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. , 1994, Journal of the National Cancer Institute.

[66]  K. Cowan,et al.  Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. , 1994, Cancer research.

[67]  M. Takeichi.  Cadherins in cancer: implications for invasion and metastasis. , 1993, Current opinion in cell biology.

[68]  W. Yue,et al.  MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[69]  M. Gottesman,et al.  Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. , 1992, Journal of the National Cancer Institute.

[70]  I. Roninson,et al.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.

[71]  I. Pastan,et al.  Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. , 1986, The Journal of biological chemistry.

[72]  C. Osborne,et al.  Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. , 1985, Cancer research.